We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
Read MoreHide Full Article
Varian Medical Systems, Inc. reported fourth-quarter fiscal 2020 adjusted earnings per share (EPS) of $1.12, beating the Zacks Consensus Estimate of 98 cents by 14.3%. The figure however fell 7.4% year over year.
For fiscal 2020, adjusted EPS came at $3.91, beating the Zacks Consensus Estimate of $3.77 by 3.7%. Moreover, the bottom line fell 15.6% year over year.
Revenue Details
The company reported revenues of $850.5 million, which beat the consensus mark of $832 million by 2.2%. However, revenues fell 3.2% year over year and 4% at constant currency (cc).
For fiscal 2020, the company reported revenues of $3.17 billion, which beat the consensus mark of $3.15 billion by 0.6%. Revenues fell 2% year over year and 1% at constant currency (cc).Organically it fell 4%.
Segment Details
Oncology Systems: Revenues totaled $800.4 million, down 2.3% year over year.
As a whole, gross orders fell 8% from the year-ago quarter to $1 billion.
Orders in the United States dropped 19% year over year, which included a 17% decline in North America. In EMEA, orders fell 4% year over year, while APAC orders rose 14% year over year.
Proton Solutions: Revenues at the segment fell 8.1% to $38.5 million.
Other: Revenues at this segment grossed $12million, down 33%. For investors’ notice, the segment comprises Interventional Solutions business, including cryoablation, embolic microspheres, and microwave ablation. Moreover, it comprises investments in cardiac radioablation.
Margins
Total gross profit in the reported quarter was $375 million, down 2.6% year over year. Gross margin in the reported quarter was 44.1% of net revenues, up 30 basis points (bps).
Adjusted operating profit came in at $123 million, down 10.7% year over year.As a percentage of revenues, adjusted operating margin was 14.5%, down 122 bps.
Varian Medical Systems, Inc. Price, Consensus and EPS Surprise
The company exited fiscal 2020 with $766.1 million in cash and cash equivalents, compared with $531.4 million in the year-ago period. Cumulative net cash provided by operating activities at the end of fiscal 2020 was $266 million compared with $117.8 million in the year-ago period.
Guidance
In the quarter under review, the company did not issue any guidance due to the continued uncertainty surrounding the magnitude and duration of the COVID-19 pandemic.
Our Take
Varian exited fiscal 2020 on a strong note. Expansion in gross margin is an added positive. Management is optimistic about the completed acquisitions of CyberHeart, Cancer Treatment Services International, Endocare and Alicon. The receipt of 10 Ethos orders (including five in North America and five in EMEA) and one Proton order buoys optimism. Moreover, the company’s merger agreement with Siemens Healthineers will enable it to expand its renowned customer care, thereby offering service to clinicians and patients from the very first stage of cancer. This development instills optimism in the stock.
On the flip side, the company saw revenue decline at each of its core operating segment in the quarter. Oncology gross orders also fell in the quarter, especially in EMEA. Contraction in adjusted operating margin is concerning.
Zacks Rank and Key Picks
Varian currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks yet to report earnings include InsuletCorporation (PODD - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Quidel Corporation (QDEL - Free Report) .
The Zacks Consensus Estimate for Insulet’s third-quarter 2020 adjusted EPS is currently pegged at 6 cents and for revenues is at $220.89 million. The company currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for its third-quarter 2020 adjusted EPS is currently pegged at $1.41. The same for revenues stands at $666.7 million.
The Zacks Consensus Estimate for Quidel’s third-quarter 2020 revenues is pegged at $476.1 million, suggesting a year-over-year improvement of 276.4%. The same for EPS stands at $4.58, indicating growth of 554.3% from the year-ago reported figure. The company currently sports a Zacks Rank #1.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Image: Shutterstock
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
Varian Medical Systems, Inc. reported fourth-quarter fiscal 2020 adjusted earnings per share (EPS) of $1.12, beating the Zacks Consensus Estimate of 98 cents by 14.3%. The figure however fell 7.4% year over year.
For fiscal 2020, adjusted EPS came at $3.91, beating the Zacks Consensus Estimate of $3.77 by 3.7%. Moreover, the bottom line fell 15.6% year over year.
Revenue Details
The company reported revenues of $850.5 million, which beat the consensus mark of $832 million by 2.2%. However, revenues fell 3.2% year over year and 4% at constant currency (cc).
For fiscal 2020, the company reported revenues of $3.17 billion, which beat the consensus mark of $3.15 billion by 0.6%. Revenues fell 2% year over year and 1% at constant currency (cc).Organically it fell 4%.
Segment Details
Oncology Systems: Revenues totaled $800.4 million, down 2.3% year over year.
As a whole, gross orders fell 8% from the year-ago quarter to $1 billion.
Orders in the United States dropped 19% year over year, which included a 17% decline in North America. In EMEA, orders fell 4% year over year, while APAC orders rose 14% year over year.
Proton Solutions: Revenues at the segment fell 8.1% to $38.5 million.
Other: Revenues at this segment grossed $12million, down 33%. For investors’ notice, the segment comprises Interventional Solutions business, including cryoablation, embolic microspheres, and microwave ablation. Moreover, it comprises investments in cardiac radioablation.
Margins
Total gross profit in the reported quarter was $375 million, down 2.6% year over year. Gross margin in the reported quarter was 44.1% of net revenues, up 30 basis points (bps).
Adjusted operating profit came in at $123 million, down 10.7% year over year.As a percentage of revenues, adjusted operating margin was 14.5%, down 122 bps.
Varian Medical Systems, Inc. Price, Consensus and EPS Surprise
Varian Medical Systems, Inc. price-consensus-eps-surprise-chart | Varian Medical Systems, Inc. Quote
Cash Position
The company exited fiscal 2020 with $766.1 million in cash and cash equivalents, compared with $531.4 million in the year-ago period. Cumulative net cash provided by operating activities at the end of fiscal 2020 was $266 million compared with $117.8 million in the year-ago period.
Guidance
In the quarter under review, the company did not issue any guidance due to the continued uncertainty surrounding the magnitude and duration of the COVID-19 pandemic.
Our Take
Varian exited fiscal 2020 on a strong note. Expansion in gross margin is an added positive. Management is optimistic about the completed acquisitions of CyberHeart, Cancer Treatment Services International, Endocare and Alicon. The receipt of 10 Ethos orders (including five in North America and five in EMEA) and one Proton order buoys optimism. Moreover, the company’s merger agreement with Siemens Healthineers will enable it to expand its renowned customer care, thereby offering service to clinicians and patients from the very first stage of cancer. This development instills optimism in the stock.
On the flip side, the company saw revenue decline at each of its core operating segment in the quarter. Oncology gross orders also fell in the quarter, especially in EMEA. Contraction in adjusted operating margin is concerning.
Zacks Rank and Key Picks
Varian currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks yet to report earnings include Insulet Corporation (PODD - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Quidel Corporation (QDEL - Free Report) .
The Zacks Consensus Estimate for Insulet’s third-quarter 2020 adjusted EPS is currently pegged at 6 cents and for revenues is at $220.89 million. The company currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for its third-quarter 2020 adjusted EPS is currently pegged at $1.41. The same for revenues stands at $666.7 million.
The Zacks Consensus Estimate for Quidel’s third-quarter 2020 revenues is pegged at $476.1 million, suggesting a year-over-year improvement of 276.4%. The same for EPS stands at $4.58, indicating growth of 554.3% from the year-ago reported figure. The company currently sports a Zacks Rank #1.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Check out the 2020 Election Stock Report >>